Enzo Biochem's Clinical Lab Subsidiary Announces New Senior Staff Additions


Enzo Biochem, Inc. (NYSE:ENZ), a biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications and laboratory services, today announced that its subsidiary, Enzo Clinical Labs, Inc., has added two key personnel to its senior management group.

Karl W. Lanks, M.D., PhD., who for the last 14 years was the Chairman of the Department of Pathology and Laboratory Medicine and Director of Laboratories at the Staten Island University Hospital in New York, has been named Enzo's Clinical Lab's new Medical Director.

Nena Chin, M.D., Ph.D., a Clinical Associate Professor of Pathology at SUNY-Downstate Medical Center, has been named to the new position of Associate Medical Director, and Scientific Director of the Company's new molecular pathology unit.

"We are pleased to add these two highly qualified professionals to Enzo Clinical Labs' management team, said Shahram Rabbani, President of Enzo Clinical Labs, Inc. "We look forward to their contribution in positioning Enzo Clinical Labs as we move to expand our opportunities in the rapidly evolving new molecular and genetic diagnostics markets."

"Dr. Lanks and Dr. Chin bring extensive pathology experience that will be valuable in our expansion plans. Dr. Lanks has managed clinical laboratories performing in excess of two million clinical tests per year, and has an extensive background in cellular and molecular biology. He is a full Professor of Pathology at SUNY-Downstate Medical Center. Dr. Chin, who has authored more than 30 peer-reviewed articles, and is a Clinical Associate Professor of Pathology at SUNY-Downstate Medical Center, has established and run several immunopathology labs over the last two decades. As we continue to expand our capabilities in this fast growing sector of the clinical lab, her knowledge of this field combined with the technical expertise of our scientific group will be a key asset."

Added Barry Weiner, President of Enzo Biochem, Inc., "These appointments represent our Company's continuing program to grow Enzo with experienced professionals having a wide range of relevant expertise."

Enzo Clinical Labs is a leading regional laboratory serving the greater New York/New Jersey region which covers more than 20 million individuals. The laboratory offers a full menu of state-of-the-art diagnostic procedures in areas such as chemistry, microbiology, hematology, blood banking as well as pathology and genetic testing. Enzo Clinical Labs is currently undergoing an expansion in the number and complexity of tests performed in-house. Enzo Labs maintains a network of more than 20 patient service centers, a satellite laboratory in New York City, and a full-service phlebotomy department.

About Enzo

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn's Disease. Pre-clinical research is being conducted on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 200 patents worldwide. For more information visit our website www.enzo.com.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

Source: Enzo Biochem, Inc.